# GNE-3511

| | |
|---|---|
| **Cat. No.:** | HY-12947 |
| **CAS No.:** | 1496581-76-0 |
| **Molecular Formula:** | $C_{23}H_{26}F_2N_6O$ |
| **Molecular Weight:** | 440.49 |
| **Target:** | MAP3K |
| **Pathway:** | MAPK/ERK Pathway |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 31.25 mg/mL (70.94 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.2702 mL | 11.3510 mL | 22.7020 mL |
| 5 mM | 0.4540 mL | 2.2702 mL | 4.5404 mL |
| 10 mM | 0.2270 mL | 1.1351 mL | 2.2702 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

GNE-3511 is a dual leucine zipper kinase (DLK) inhibitor with a $K_i$ of 0.5 nM.

## CUSTOMER VALIDATION

- Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):E9899-E9908.
- Cell Rep. 2019 Sep 3;28(10):2581-2593.e5.
- J Innate Immun. 2021 Jun 25;1-10.
- Washington State University. Division of Biology and Biomedical Sciences Neurosciences. 2021 Oct.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. Patel S et al. Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. J Med Chem. 2015 Jan 8;58(1):401-18.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA